Physician profile
Romel C Wrenn
NPI 1255302717
$21,821.00
in general payments reported to CMS, 2019-2025
27 companies · $4,237 in 2025
The $4,237 reported for 2025 was more than what 81% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $178 · 2021: $417 · 2022: $787 · 2023: $1,526 · 2024: $138 · 2025: $4,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,534 · Food and Beverage: $2,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,534.01 |
| Food and Beverage | $2,367.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $11,375.21 | 2019 | |
| Abbott Laboratories | $2,651.36 | 2022-2025 | Xience Skypoint |
| Ge Healthcare | $2,293.59 | 2019 | |
| Medtronic, INC. | $2,282.17 | 2021-2025 | Micra, Selectsecure, Azure Xt Dr Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $1,029.28 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $276.06 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $269.81 | 2019-2025 | |
| Boston Scientific Corporation | $265.86 | 2023 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $197.30 | 2019-2023 | Repatha |
| Chiesi USA, INC. | $193.45 | 2019-2023 | Kengreal, Cleviprex |
| Pfizer INC. | $154.14 | 2020-2025 | |
| Akcea Therapeutics, INC. | $124.43 | 2019 | |
| Merck Sharp & Dohme LLC | $113.11 | 2021-2025 | Verquvo |
| Medtronic Vascular, INC. | $105.64 | 2019-2020 | |
| Shockwave Medical, INC | $75.01 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $66.25 | 2023 | Remede System |
| Janssen Pharmaceuticals, INC | $63.29 | 2019-2022 | |
| Braemar Manufacturing, LLC | $54.47 | 2019 | |
| Anumana, INC. | $45.69 | 2025 | Ecg-Ai Lef |
| Bridgebio Pharma, INC. | $41.19 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $32.49 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.29 | 2022 | |
| Lundbeck LLC | $22.01 | 2019 | |
| Philips North America LLC | $18.37 | 2019 | |
| Amarin Pharma, INC. | $14.42 | 2020 | |
| Baxter Healthcare | $14.14 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Bardy Diagnostics, INC. | $9.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romel Wrenn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.